Go to main content

A single-center comparison of thymoglobulin, basiliximab, and alemtuzumab induction therapy in simultaneous pancreas-kidney transplant patients

Khan, Lubna; Elstrott, Ben; Olyaei, Ali; Lockridge, Joseph; Scott, David
2020
Get Accessible Copy
Download
Add to Basket
Cite

There are few studies that compare the safety of multiple induction therapies in simultaneous pancreas-kidney transplant (SPKT) patients. The purpose of this study is to compare basiliximab, thymoglobulin (ATG), and alemtuzumab according to HLA matching to assess allograft survival, rejection rate, and post-operative complications.

Title
A single-center comparison of thymoglobulin, basiliximab, and alemtuzumab induction therapy in simultaneous pancreas-kidney transplant patients
Creator
Khan, Lubna : Oregon Health and Science University
Elstrott, Ben : Oregon Health and Science University
Olyaei, Ali : Oregon Health and Science University
Lockridge, Joseph : Oregon Health and Science University
Scott, David : Oregon Health and Science University
Meeting Name
Research Week, Oregon Health and Science University, 2020
Publisher
Oregon Health and Science University
Date
2020
Subjects
Keywords
DOI
https://doi.org/10.6083/9p290b031
Language
English
Content Type
Abstract
Copyright Status
In copyright - joint owners
Usage Statement
Record ID
8271
Record Created
2023-06-29
Disclaimer

These documents are archival records. They are retained for historical reference only.

Need an accessible version? Use the ‘Get Accessible Copy’ link above.

Record Appears in
OHSU Works > Events > Research Week
All Records

Metric
From
To
Interval
Export
Download Full History